TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Berg Balance Scale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cuff pressure maintenance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: echocardiographic parameters of myocardial dimensions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: systolic and diastolic function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: noninvasive endothelial cell function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Efficacy of fexofenadine in allergic rhinitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of fexofenadine in allergic rhinitis
Endpoint domain: Adverse events/effects
Primary endpoint: Positive attitudes toward combining alcohol and sex
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive attitudes toward drinking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Positive attitudes toward smoking
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Postoperative morphine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reducing prejudicial attitudes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: reducing avoidance intent towards people living with HIV
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: increasing institutional support in the hospitals
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Memory test scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percentage of children feeling no pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time required for treatment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: global health
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: FIQ (Fibromyalgia Impact Questionnaire)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: pain at worst site
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Deep Vein Thrombosis (DVT)
Endpoint domain: Adverse events/effects
Primary endpoint: Venous Thromboembolism (VTE)
Endpoint domain: Adverse events/effects
Primary endpoint: Major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Marginal bone loss (MBL) at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: flare response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carbamazepine epoxide metabolite concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: diagnosed allergic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: IgE-associated allergic disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of patients within the iPTH guideline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in iPTH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Improvement in Ca levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Weight loss from baseline body weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients achieving weight loss of at least 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean WOMAC score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bioavailability of 6-thioguanine nucleotides (6-TGN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Leucocyte depletion dosages
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preference for oral liquid over capsules
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Plasma esomeprazole concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reliever medication usage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Atopic dermatitis scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion of blood samples from negative to positive during operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Positive Incremental Area Under the Curve (pIAUC) for glucose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Positive Incremental Area Under the Curve (pIAUC) for insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: beneficial health effects from qigong
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in RMQ scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nursing satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Sustained smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful outcome of endodontic treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall improvement in skin appearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Rate of clinical response at 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for colectomy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Health-related quality of life (HRQOL) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prevalence of hypothermia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of asymptomatic white refractile deposits
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Nonprogressive conjunctival lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Regression of conjunctival lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Growth rate of GA lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in NL‐BCVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adverse events (delayed dark adaptation, chromatopsia, visual impairment, erythropsia)
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of bowel cleansing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Tolerability of bowel cleansing
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Latch, Audible swallowing, nipple Type, Comfort, Hold score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decline in serum sodium postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemoglobin drop postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Total acute complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Beta 1 integrin expression on T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: CD40L expression on T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: T cell proliferation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: FMS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lean mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Biaxial flexural strength of zirconia core material
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sitting-time at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PEDI functional mobility scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of CDSS scores from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of extrapyramidal symptoms (EPS)
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of hyperprolactinemia-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Motor Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Width of the joint space of the hip
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of success (decrease of pain > 50%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: composite of death, myocardial infarction, or repeat target lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: repeat target lesion revascularization
Endpoint domain: Mortality/survival
Primary endpoint: Graft survival rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Masticatory muscle activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effectiveness of Internet-based PCST protocol for persistent hip pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Enhancement of clinical practice
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Correct responses regarding bed net practices and attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reported use of nets every night
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: 10-year recurrence-free survival
Endpoint domain: Mortality/survival
Primary endpoint: Clinic morning peak expiratory flow improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Asthma symptom scores improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increased ICF in migraineurs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: PFM strength improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: frequency of urination
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: detrusor compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in femoral trochanter BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in total hip BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Increase of CD4(+)CD25(+)Foxp3(+) Treg cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Increase of CD4(+)CD25(‐)Foxp3(+) Treg cells in peripheral blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in CRP over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in eyelash length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in steepest and flattest meridians
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal or newborn rehospitalization within 10 days postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal or newborn urgent clinic visits within 10 days postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding discontinuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comfort level of the Proclear lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In vivo dehydration of the Proclear lens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: biliary fistula rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Circulating anti-D detectable at delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean maximum observed plasma concentration (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to Cmax (Tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain burden at rest
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postprandial blood glucose (BG) control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Equivalent efficacy between GP2017 and ref‐ADMB
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in microbial counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Physical function of lower and upper extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 6 Minute Walk Test (6 MWT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diverticulitis relapse incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean values of TIQ at 24 months
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average additional drug consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: lung water content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: blood oxygenation (Pao(2)/Fio(2) ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery without treatment
Endpoint domain: Mortality/survival
Primary endpoint: Albumin synthesis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean difference in FEV(1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AUC(0,5 h) values for fluticasone and budesonide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clearance rate of PWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cumulative success rate
Endpoint domain: Mortality/survival
Primary endpoint: Evolution from active to degenerative phase
Endpoint domain: Mortality/survival
Primary endpoint: Evolution from degenerative phase to disappearance
Endpoint domain: Mortality/survival
Primary endpoint: Contrast nephropathy incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Major depressive disorder recovery rates
Endpoint domain: Mortality/survival
Primary endpoint: Beck Depression Inventory‐II scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone probing depth (BP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Actual bone level (SBL)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual acuity at 3 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Development of iris neovascularization (INV) or angle neovascularization (ANV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Conversion of eyes from perfusion to ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attenuation of sufentanil-induced cough
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significantly abnormal Vscan results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 1-legged hop test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: KOOS quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: AP knee laxity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative risk of recurrent parasitemia on day 42
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Mean duration of gametocyte carriage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Subject reported pain with biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Provider-reported ease of use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Size and severity of nasal-ala pressure sores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: serum E(2) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: heart rate variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: shoulder range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CRP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Wagner grade
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient satisfaction with care
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Immediate anastomotic patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Delayed anastomotic patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rates of sperm presence on microscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Duration of catheterization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acute renal dysfunction occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: anesthesia recovery times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hospital discharge times
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: parent‐child separation and anesthesia induction scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Control of nasal symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life impairment
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Need for additional terfenadine
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Stroke risk reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mask leak
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: lowest oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cough scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sputum eosinophil counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ADH levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Willingness to pay for fortification
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Efficacy of SQ tree SLIT-tablet compared to placebo
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of SQ tree SLIT-tablet compared to placebo
Endpoint domain: Adverse events/effects
Primary endpoint: MR volume measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Flourishing scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Life satisfaction scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Flexibility of day care
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Return to paid employment
Endpoint domain: Life impact
Endpoint subdomain: Economic circumstances
Primary endpoint: net ultrafiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: transcapillary ultrafiltration rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: effective lymphatic absorption rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Triglycerides improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: LLANTO scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FPS-R scale score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in insulin sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Retention of functional motor skills
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Index of Erectile Function-Erectile Function domain score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of 'Yes' responses to Sexual Encounter Profile questions 2 and 3
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning